Altimmune on PEth to phase III in AUD with pemvi

Source Summary

Altimmune Inc. and Wall Street are mulling the size and scope of a phase III trial after positive top-line results were made public from the Reclaim phase II trial with pemvidutide (pemvi), a balanced glucagon/GLP-1 dual receptor agonist, in patients with moderate to severe alcohol use disorder (AUD). CEO Jerry Durso called the Reclaim data “the most robust we’ve seen” in the condition.